Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.
View Top Employees from Pharvaris| Website | https://pharvaris.com |
| Revenue | $11.5 million |
| Funding | $164.3 million |
| Employees | 95 (70 on RocketReach) |
| Founded | 2015 |
| Phone | +31 71 203 6410 |
| Technologies |
JavaScript,
HTML,
PHP
+32 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing, Pharmaceuticals, Biotechnology, Healthcare, Science and Engineering, Life Science, Pharmaceutical, Health Care |
| SIC | SIC Code 2834 Companies, SIC Code 87 Companies, SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 54171 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 541713 Companies, NAICS Code 5417 Companies |
Looking for a particular Pharvaris employee's phone or email?
Pharvaris Questions
The Pharvaris annual revenue was $11.5 million in 2024.
Emily Jochim is the Vice President, Head of Clinical Development Operations of Pharvaris.
70 people are employed at Pharvaris.
The NAICS codes for Pharvaris are [3254, 54171, 32, 325, 541, 54, 541713, 5417].
The SIC codes for Pharvaris are [2834, 87, 28, 283].
Top Pharvaris Employees
-
2
-
21
-
21
-
45+
-
5+5+
Related Companies
